Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide and Etoposide in Relapsed/Refractory NK/T-cell Lymphoma
NCT04490590Phase 4Unknown
- Start
- Oct 2016
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of tucidinostat in Natural killer T-cell lymphoma (NKTL). Status: unknown.
02
Drugs
tucidinostat
03
Conditions
Natural killer T-cell lymphoma (NKTL)
Beyond the preview
Go deeper on NCT04490590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04490590.